Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein-Barr virus infected human B cell lymphoma in SCID mouse

Cancer Science

Volumn 94, Issue 9, 2003, Pages 796-801

  Gan, Runliang ^a   Yin, Zhihua ^b   Liu, Tengfei ^b   Wang, Lijiang ^a   Tang, Yunlian ^a   Song, Ying ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER INCIDENCE; CANCER SURVIVAL; CHIMERA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOHISTOCHEMISTRY; LIFESPAN; MALE; MORPHOLOGY; MORTALITY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL;

ANIMALS; CHIMERA; CYCLOSPORINE; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT VS HOST DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE TRANSFUSION; LEUKOCYTES; LYMPHOMA, B-CELL; MICE; MICE, SCID; RECEPTORS, INTERLEUKIN-2;

EID: 0141892729     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01521.x     Document Type: Article

References (32)

1. Papesch M, Watkins R. Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol 2001; 26: 3-8.
2. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003; 63: 2028-32.
3. Westphal EM, Mauser A, Swenson J, Davis MG, Talarico CL, Kenney SC. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies. Cancer Res 1999; 59: 1485-91.
4. Henry S, Sacaze C, Berrajah L, Karray H, Drira M, Hammami A, Icart J, Mariame B. In nasopharyngeal carcinoma-bearing patients, tumors and lymphocytes are infected by different Epstein-Barr virus strains. Int J Cancer 2001; 91: 698-704.
5. Baran-Marszak F, Fagard R, Girard B, Camilleri-Broet S, Zeng F, Lenoir GM, Raphael M, Feuillard J. Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines. Lab Invest 2002; 82: 1463-79.
6. Gan R, Lan K, Yin Z, Wang L, Xiu L, Yao K. Development of human B-cell lymphomas induced by Epstein-Barr virus in SCID mouse. Chin J Clin Oncol 2002; 29: 733-8.
7. Funakoshi S, Beckwith M, Fanslow W, Longo DL, Murphy WJ. Epstein-Barr virus-induced human B-cell lymphoma arising in Hu-PBL/SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention. Pathobiology 1995; 63: 133-42.
8. Fuzzati-Armentero MT, Duchosal MA. Hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease. Histol Histopathol 1998; 13: 155-68.
9. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-66.
10. Asano M, Gundry SR, Izutani H, Cannarella SN, Fagoaga O, Bailey LL. Baboons undergoing orthotopic concordant cardiac xenotransplantation surviving more than 300 days: effect of immunosuppressive regimen. J Thorac Cardiovasc Surg 2003; 125: 60-9.
11. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75: 772-80.
12. Sokol DK, Molleston JP, Filo RS, Van Valer J, Edwards-Brown M. Tacrolimus (FK506)-induced mutism after liver transplant. Pediatr Neurol 2003; 28: 156-8.
13. Arranz R, Conde E, Rodriguez-Salvanes F, Pajuelo FJ, Cabrera R, Sanz MA, Petit J, Bueno J, Maldonado J, Odriozola J, Conde JG, Brunet S, Carreras E, Iriondo A, Fernandez-Ranada JM, Marin P. CSA-based post-graft immunosuppression: the main factor for improving outcome of allograft patients with acquired aplastic anemia. Bone Marrow Transplant 2002; 29: 205-11.
14. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-7.
15. Osorio LM, Rottenberg M, Jondal M, Chow SC. Simultaneous cross-linking of CD6 and CD28 induced cell proliferation in resting T cells. Immunology 1998; 93: 358-65.
16. Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000; 59 Suppl 1: i109-14.
17. Casiraghi F, Ruggenenti P, Noris M, Locatelli G, Perico N, Perna A, Remuzzi G. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. Transplantation 1997; 63: 1508-14.
18. Lun A, Cho MY, Muller C, Staffa G, Bechstein WO, Radke C, Neuhaus P, Renz H. Diagnostic value of peripheral blood T-cell activation and soluble IL-2 receptor for acute rejection in liver transplantation. Clin Chim Acta 2002; 320: 69-78.
19. Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Roum Arch Microbiol Immunol 2001; 60: 183-201.
20. Papadaki HA, Coulocheri S, Eliopoulos GD. Patients with chronic idiopathic neutropenia of adults have increased serum concentrations of inflammatory cytokines and chemokines. Am J Hematol 2000; 65: 271-7.
21. Porcel JM, Gazquez I, Vives M, Perez B, Rubio M, Rivas MC. Diagnosis of tuberculous pleuritis by the measurement of soluble interleukin 2 receptor in pleural fluid. Int J Tuberc Lung Dis 2000; 4: 975-9.
22. Fukuchi Y, Miyakawa Y, Kizaki M, Umezawa A, Shimamura K, Kobayashi K, Kuramochi T, Hata J, Ikeda Y, Tamaoki N, Nomura T, Ueyama Y, Ito M. Human acute myelo-blastic leukemia-ascites model using the human GMCSF- and IL-3-releasing transgenic SCID mice. Ann Hematol 1999; 78: 223-31.
23. Fauser AA, Basara N, Blau IW, Kiehl MG. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study. Bone Marrow Transplant 2000; 25 Suppl 2: S27-31.
24. Ji S, Chen H, Wang H, Ma J, Pan S, Xue M, Zhu L, Liu J, Xiao M, Zhou L. Low incidence of severe aGVHD, and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells. Chin Med J 2001; 114: 191-5.
25. Kroger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schafer-Eckart K, Wittkowsky G, Schmitz N, Kruger W, Zabelina T, Renges H, Ayuk F, Krull A, Zander A. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma: a phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant 2003; 31: 973-9.
26. Van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol 1999; 107: 169-75.
27. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation. Bio Drugs 2003; 17: 147-54.
28. Shaw KT, Ho AM, Raghavan A, Kim J, Jain J, Park J, Sharma S, Rao A, Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92: 11205-9.
29. Krook H, Wennberg L, Hagberg A, Song Z, Groth CG, Korsgren O. Immunosuppressive drugs in islet xenotransplantation: a tool for gaining further insights in the mechanisms of the rejection process. Transplantation 2002; 74: 1084-9.
30. Miyamono T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K, Harada M, Niho Y. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185-90.
31. Economidou J, Barkis J, Demetriou Z, Avgerinou G, Psarra K, Degiannis D, Vareltzidis A, Katsambas A. Effects of cyclosporin A on immune activation markers in patients with active psoriasis. Dermatology 1999; 199: 144-8.
32. Mathias C, Mick R, Grupp S, Duffy K, Harris F, Laport G, Stadtmauer E, Luger S, Schuster S, Wasik MA, Porter DL. Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. J Hematother Stem Cell Res 2000; 9: 393-400.